Establishing a Foundation for Early Screening of Sleep Disorders and Monitoring Treatment Progress

Chongkundang announced on the 4th that it has signed a domestic joint sales agreement with sleep tech company A-Sleep for the digital diagnostic support device for sleep apnea, 'AppNoTrack'.

Kim Youngju, CEO of Chongkundang (right), and Lee Dongheon, CEO of A-Sleep, are taking a commemorative photo after signing a domestic joint sales contract for 'AppNoTrack' at Chongkundang Chungjeongno headquarters in Seodaemun-gu, Seoul on the 3rd. Chongkundang

Kim Youngju, CEO of Chongkundang (right), and Lee Dongheon, CEO of A-Sleep, are taking a commemorative photo after signing a domestic joint sales contract for 'AppNoTrack' at Chongkundang Chungjeongno headquarters in Seodaemun-gu, Seoul on the 3rd. Chongkundang

View original image

This agreement is a strategic partnership aimed at establishing a digital early diagnosis system in Korea's medical field and building an integrated care model for sleep apnea and high-risk chronic diseases. The two companies plan to supply AppNoTrack to hospitals and clinics nationwide.


AppNoTrack is a digital diagnostic support medical device that uses artificial intelligence to analyze breathing sounds during sleep, recorded via smartphone, to screen for the risk of sleep apnea at an early stage. It allows users to conduct sleep tests independently without additional equipment. Based on the test results, hospitals and clinics can quickly proceed with follow-up diagnosis and treatment decisions for high-risk patients.


In particular, it can be used as a primary screening medical device for high-risk groups for sleep apnea, such as those with obesity, diabetes, hypertension, or cardiovascular diseases. It can also be expanded into a digital sleep care platform that covers progress monitoring and observation of treatment response in conjunction with therapies such as positive airway pressure treatment.


This product was designated as an innovative medical device by the Ministry of Food and Drug Safety in 2024. It received approval as a Class 2 medical device and for non-reimbursed prescriptions using only a smartphone, and has been prescribed at major general hospitals since this year. Its AI algorithm, trained on multicenter clinical data, over 6 million real sleep sound cases, and more than 10,000 hospital polysomnography datasets, has demonstrated high performance with 87% sensitivity, 92% specificity, and 97% negative predictive value. These results have been validated through dozens of presentations at international academic conferences, including SCI-level journals and the World Sleep Congress.


Lee Dongheon, CEO of A-Sleep, stated, "This agreement marks the beginning of the full-scale expansion of digital technology-based sleep medicine into routine clinical practice. Through a sleep apnea care model that connects early diagnosis with treatment monitoring, we aim to provide better treatment for patients, more precise decision-making for healthcare professionals, and scalable digital solutions for pharmaceutical companies."



Kim Youngju, CEO of Chongkundang, said, "AppNoTrack is an innovative product that significantly improves access to sleep apnea diagnosis with a simple measurement method. Through this partnership, we will enhance our expertise in the digital medical device sector and expand Chongkundang's portfolio of chronic disease therapeutics based on IT technology, building an integrated care model."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing